205 related articles for article (PubMed ID: 20483742)
41. Mechanisms of tolerance induced by transforming growth factor-beta-treated antigen-presenting cells: CD8 regulatory T cells inhibit the effector phase of the immune response in primed mice through a mechanism involving Fas ligand.
Kosiewicz MM; Alard P; Liang S; Clark SL
Int Immunol; 2004 May; 16(5):697-706. PubMed ID: 15096489
[TBL] [Abstract][Full Text] [Related]
42. Differential activation of human gammadelta cells by nonpeptide phosphoantigens.
Sireci G; Espinosa E; Di Sano C; Dieli F; Fournié JJ; Salerno A
Eur J Immunol; 2001 May; 31(5):1628-35. PubMed ID: 11465120
[TBL] [Abstract][Full Text] [Related]
43. Requirement for CD4+ T cells in the gammadelta T cell proliferative response to Daudi Burkitt's lymphoma.
Burns J; Lobo S; Bartholomew B
Cell Immunol; 1996 Nov; 174(1):19-24. PubMed ID: 8929450
[TBL] [Abstract][Full Text] [Related]
44. Activated alpha 2-macroglobulin reverses the immunosuppressive activity in human breast cancer cell-conditioned medium by selectively neutralizing transforming growth factor-beta in the presence of interleukin-2.
Harthun NL; Weaver AM; Brinckerhoff LH; Deacon DH; Gonias SL; Slingluff CL
J Immunother; 1998 Mar; 21(2):85-94. PubMed ID: 9551359
[TBL] [Abstract][Full Text] [Related]
45. CD28 costimulation overcomes transforming growth factor-beta-mediated repression of proliferation of redirected human CD4+ and CD8+ T cells in an antitumor cell attack.
Koehler H; Kofler D; Hombach A; Abken H
Cancer Res; 2007 Mar; 67(5):2265-73. PubMed ID: 17332357
[TBL] [Abstract][Full Text] [Related]
46. Inhibition of caspases maintains the antineoplastic function of gammadelta T cells repeatedly challenged with lymphoma cells.
Ferrarini M; Consogno G; Rovere P; Sciorati C; Dagna L; Resta D; Rugarli C; Manfredi AA
Cancer Res; 2001 Apr; 61(7):3092-5. PubMed ID: 11306492
[TBL] [Abstract][Full Text] [Related]
47. Regulation of lymphokine-activated killer activity and pore-forming protein gene expression in human peripheral blood CD8+ T lymphocytes. Inhibition by transforming growth factor-beta.
Smyth MJ; Strobl SL; Young HA; Ortaldo JR; Ochoa AC
J Immunol; 1991 May; 146(10):3289-97. PubMed ID: 1827481
[TBL] [Abstract][Full Text] [Related]
48. Phosphoantigens and butyrophilin 3A1 induce similar intracellular activation signaling in human TCRVγ9+ γδ T lymphocytes.
Decaup E; Duault C; Bezombes C; Poupot M; Savina A; Olive D; Fournié JJ
Immunol Lett; 2014 Sep; 161(1):133-7. PubMed ID: 24925024
[TBL] [Abstract][Full Text] [Related]
49. The gene expression profile of phosphoantigen-specific human γδ T lymphocytes is a blend of αβ T-cell and NK-cell signatures.
Pont F; Familiades J; Déjean S; Fruchon S; Cendron D; Poupot M; Poupot R; L'faqihi-Olive F; Prade N; Ycart B; Fournié JJ
Eur J Immunol; 2012 Jan; 42(1):228-40. PubMed ID: 21968650
[TBL] [Abstract][Full Text] [Related]
50. Induction of cytotoxic T lymphocytes by CEA peptide-pulsed γδ T-cells isolated from patients with advanced cancer.
Yamasaki A; Onishi H; Morisaki T; Katano M
Anticancer Res; 2011 Jul; 31(7):2419-24. PubMed ID: 21873153
[TBL] [Abstract][Full Text] [Related]
51. Bromohydrin pyrophosphate enhances antibody-dependent cell-mediated cytotoxicity induced by therapeutic antibodies.
Gertner-Dardenne J; Bonnafous C; Bezombes C; Capietto AH; Scaglione V; Ingoure S; Cendron D; Gross E; Lepage JF; Quillet-Mary A; Ysebaert L; Laurent G; Sicard H; Fournié JJ
Blood; 2009 May; 113(20):4875-84. PubMed ID: 19278954
[TBL] [Abstract][Full Text] [Related]
52. Adoptive immunotherapy of cancer using ex vivo expanded human gammadelta T cells: A new approach.
Dokouhaki P; Han M; Joe B; Li M; Johnston MR; Tsao MS; Zhang L
Cancer Lett; 2010 Nov; 297(1):126-36. PubMed ID: 20537791
[TBL] [Abstract][Full Text] [Related]
53. [Tgammadelta lymphocytes in oncology: unconventional killer lymphocytes].
Catros V; Toutirais O; Bouet F; Cabillic F; Desille M; Fournié JJ
Med Sci (Paris); 2010 Feb; 26(2):185-91. PubMed ID: 20188051
[TBL] [Abstract][Full Text] [Related]
54. Human γδ T-cell responses in infection and immunotherapy: common mechanisms, common mediators?
Riganti C; Massaia M; Davey MS; Eberl M
Eur J Immunol; 2012 Jul; 42(7):1668-76. PubMed ID: 22806069
[TBL] [Abstract][Full Text] [Related]
55. Protective role of the inflammatory CCR2/CCL2 chemokine pathway through recruitment of type 1 cytotoxic γδ T lymphocytes to tumor beds.
Lança T; Costa MF; Gonçalves-Sousa N; Rei M; Grosso AR; Penido C; Silva-Santos B
J Immunol; 2013 Jun; 190(12):6673-80. PubMed ID: 23686489
[TBL] [Abstract][Full Text] [Related]
56. Targeting γδ T lymphocytes for cancer immunotherapy: from novel mechanistic insight to clinical application.
Gomes AQ; Martins DS; Silva-Santos B
Cancer Res; 2010 Dec; 70(24):10024-7. PubMed ID: 21159627
[TBL] [Abstract][Full Text] [Related]
57. γδ T cell activation by bispecific antibodies.
Oberg HH; Kellner C; Gonnermann D; Peipp M; Peters C; Sebens S; Kabelitz D; Wesch D
Cell Immunol; 2015 Jul; 296(1):41-9. PubMed ID: 25979810
[TBL] [Abstract][Full Text] [Related]
58. Novel bispecific antibodies increase γδ T-cell cytotoxicity against pancreatic cancer cells.
Oberg HH; Peipp M; Kellner C; Sebens S; Krause S; Petrick D; Adam-Klages S; Röcken C; Becker T; Vogel I; Weisner D; Freitag-Wolf S; Gramatzki M; Kabelitz D; Wesch D
Cancer Res; 2014 Mar; 74(5):1349-60. PubMed ID: 24448235
[TBL] [Abstract][Full Text] [Related]
59. The emerging Protumor role of γδ T lymphocytes: implications for cancer immunotherapy.
Rei M; Pennington DJ; Silva-Santos B
Cancer Res; 2015 Mar; 75(5):798-802. PubMed ID: 25660949
[TBL] [Abstract][Full Text] [Related]
60. TGF-beta, T-cell tolerance and immunotherapy of autoimmune diseases and cancer.
Li MO; Flavell RA
Expert Rev Clin Immunol; 2006 Mar; 2(2):257-65. PubMed ID: 20477076
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
